BSX - Boston Scientific Corp Stock Analysis
Boston Scientific Corp (BSX) is a publicly traded company listed on the NYSE. It operates in the Medical Devices industry, part of the broader Healthcare sector. The company has a market capitalization of 130.61B, generates annual revenue of 19.35B, and reports net income of 2.79B. As of the latest data, the stock is trading at 88.07 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. This stock does not currently pay a dividend. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.28), indicating current market sentiment. Institutional ownership is reported at 93.37%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of -9.10%, trading within a 52-week range of 85.98 - 109.50.
BSX - Boston Scientific Corp
88.07
Analyst Consensus
Buy 4.28
BSX – Analyst Rating Summary
- Strong Buy: 15
- Buy: 21
- Hold: 4
- Sell: 0
- Strong Sell: 0
- Total Analysts: 40
| Index: | S&P 500 | P/E: | 47.10 | EPS (ttm): | 1.87 | Insider Own: | 0.39% | Shs Outstand: | 1.48B | Perf Week: | -9.80% |
| Market Cap: | 130.61B | Forward P/E: | 25.35 | EPS next Y: | 3.47 | Insider Trans: | -4.42% | Shs Float: | 1.48B | Perf Month: | -5.25% |
| Income(ttm): | 2.79B | PEG: | 1.56 | EPS next Q: | 0.78 | Inst Own: | 93.37% | Short Float: | 1.35% | Perf Quarter: | -9.93% |
| Revenue(ttm): | 19.35B | P/S: | 6.75 | EPS this Y: | 20.97% | Inst Trans: | 0.42% | Short Ratio: | 2.19 | Perf Half Y: | -15.02% |
| Book/sh: | 15.78 | P/B: | 5.58 | EPS next Y: | 14.43% | ROA: | 6.91% | Short Interest: | 20.01M | Perf Year: | -9.10% |
| Cash/sh: | 0.93 | P/C: | 95.13 | EPS next 5Y: | 16.29% | ROE: | 12.66% | 52W Range: | 85.98 - 109.50 | Perf YTD: | -7.64% |
| Dividend Est.: | - | P/FCF: | 34.16 | EPS past 3/5Y: | 21.99% -17.84% | ROIC: | 7.99% | 52W High: | 109.50 -19.57% | Beta: | 0.67 |
| Dividend TTM: | - | Quick Ratio: | 0.96 | Sales past 3/5Y: | 12.10% 9.30% | Gross Margin: | 62.57% | 52W Low: | 85.98 2.43% | Perf 5Y: | 141.68% |
| Dividend Ex-Date: | - | Current Ratio: | 1.51 | EPS Y/Y TTM: | 54.80% | Oper. Margin: | 17.82% | RSI (14): | 26.69 | Volatility: | 2.69% 1.86% |
| Employees: | 53000 | Debt/Eq: | 0.51 | Sales Y/Y TTM: | 21.62% | Profit Margin: | 14.43% | Recom: | 1.24 | Target Price: | 125.16 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.49 | EPS Q/Q: | 60.10% | Payout: | 0.00% | Rel Volume: | 1.89 | Prev Close: | 90.03 |
| Sales Surprise: | 1.93% | EPS Surprise: | 5.09% | Sales Q/Q: | 20.34% | Earnings: | Feb 04 BMO | Avg Volume: | 9.14M | Price: | 88.07 |
| SMA20: | -7.68% | SMA50: | -9.23% | SMA200: | -12.45% | Undervalued: 42.11% | Volume: | 17,260,950 | Change: | -2.18% | |
Graham Classic formula value: 68.98
(P/E=8 * 1g) Min value: 40.79
(current P/E * 2g) Max value: 133.8
Average value: 81.19
About Boston Scientific Corp
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.